RxDoctor Payments Data

Sonia Sharma, MD

Family Medicine · Jacksonville, FLNPI 1760656995

Payments from drug & device makers

$4,557in general payments, 2019–2025

Across 263 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$747
  • AstraZeneca$558
  • Lilly USA, LLC$431
  • Boehringer Ingelheim$306
  • Pfizer$287
  • Abbott$271
  • plus $2K from 25 others

What the payments were for

  • Food & beverage$4,557100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,557 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$89,193
Medicare patients
172
Services billed
1,427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$149,487
MounjaroTirzepatide54$59,956
TrulicityDulaglutide34$44,025
JardianceEmpagliflozin35$34,013
EliquisApixaban23$14,427
FarxigaDapagliflozin Propanediol16$13,856
LinzessLinaclotide23$13,722
TrintellixVortioxetine Hydrobromide13$9,215
XareltoRivaroxaban13$6,976
SynthroidLevothyroxine Sodium46$4,366
Verapamil Er PmVerapamil Hcl12$2,270
Rosuvastatin Calcium160$1,949
Omeprazole76$1,774
TirosintLevothyroxine Sodium12$1,588
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$747$149,487126 claims
Lilly USA, LLCMounjaro, Trulicity$431$103,98288 claims
Boehringer IngelheimJardiance$306$34,01335 claims
AbbVieLinzess, Synthroid$155$18,08869 claims
PfizerEliquis$287$14,42723 claims
AstraZenecaFarxiga$558$13,85616 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$144$9,21513 claims
Johnson & JohnsonXarelto$61$6,97613 claims
IBSA Pharma Inc.Tirosint$17$1,58812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →